Roflumilast Cream Shows Strong Tolerability in Patients with AD Failing Other Topicals: Daily Dose
Your daily dose of the clinical news you may have missed.
What We Mean When We Say "Skin of Color" in Dermatology: A Closer Look with Raj Chovatiya, MD, PhD, MSCI
Chovatiya, expert clinical dermatologist and researcher, points out that the term "skin of color" comprises a heterogenous set of topics, in an interview at AAD 2025.
Managing Atopic Dermatitis in Special Populations: Expert Insights for Primary Care
In an interview at AAD 2025, Katrina Abuabara, MD, stressed the importance of collaboration between primary care physicians and dermatologists.
Antihistamines Are a Poor Option to Treat Eczema in Older Adults: Clinical Pearl
Antihistamines for itch caused by disorders like atopic dermatitis pose more problems, like sedation and fall risk, than they provide relief, according to Daniel Butler, MD.
Emergence of Trichophyton Indotineae: A Call for Culture-Driven Antifungal Therapy
Elizabeth Swanson, MD, shares how the rise of T.indotineae, a terbinafine-resistant fungal species, has shifted her treatment approach.
Epinephrine Nasal Spray Shows Rapid Symptom Relief in Children: Daily Dose
Daniel Butler, MD, a Leader in Geriatric Dermatology, Says Focus on the Overlap in the Etiology of Itch in Older Adults
AAD 2025: Tracing the multiple pathways that contribute to chronic itch vs looking for a singular cause helps optimize choice of therapy, Butler says.
Rethinking Shingles in Children: Expert Insights for Primary Care
Shingles is increasingly being observed in healthy, immunocompetent children. Elizabeth Swanson, MD, discusses how to recognize and respond.
Measles Resurgence and Vaccine Efficacy: A Conversation with Elizabeth Swanson, MD
Dr Swanson discusses the resurgence of measles and emphasizes the safety and efficacy of the measles vaccine.
Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings
Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.
Dupilumab Cuts Food Allergy IgE Levels in Small Study: Daily Dose
Hand, Foot, and Mouth Disease Update: A Conversation with Elizabeth Swanson, MD
Elizabeth Swanson, MD, discusses the changing face of HFMD, focusing on the increasingly prevalent coxsackievirus A6 strain and its unique characteristics
JiaDe Yu, MD: When to Refer Pediatric Patients with Suspected Contact Dermatitis
In an interview at AAD 2025, Dr Yu emphasized the importance of managing contact dermatitis early and effectively to prevent long-term complications.
Advances in Understanding of Itch: A Conversation with Brian S Kim, MD, MTR, at the 2025 AAD Meeting
Brian S Kim, MD, a leading investigator in the study of itch physiology, discusses the marked progress made in understanding the sensation and targeting its treatment.
Atopic Dermatitis of Childhood Onset Significantly Impacts "Life Trajectory" According to Scars of Life Survey
The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.
Advances in Dermatology Therapeutics: Key Insights from AAD 2025
Highlights include new data on roflumilast cream 0.15%, an investigational anti-OX40 ligand monoclonal antibody, and more.
JiaDe Yu, MD: Key Signs of Allergic Contact Dermatitis in Children
AAD 2025. JiaDe Yu, MD, discusses key clinical signs of pediatric ACD, when to consider patch testing, and how identifying contact allergens can improve patient care.
Elizabeth Swanson, MD: When HSV Causes Big Dermatologic Problems
Elizabeth Swanson, MD, breaks down the role of the Herpes Simplex Virus in 3 special circumstances, part of her AAD 2025 presentation, "Big Rashes In Little Patients."
For Atopic Dermatitis, "The Treatment Drought is Over," Says Expert Dermatologist Emma Guttman, MD, PhD
AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.
Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker
Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.
